Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Frontiers in OncologyOpen Access

Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYixian GuoYSYongzhi ShanYPYueshan Piao

Discussion

Loading...

Member takes

Overview

Pilot study shows encouraging results for IRM therapy in PCNS DLBCL, suggesting potential effectiveness and safety.

Key Points

  • IRM therapy achieved a 100% overall response rate in a small cohort of PCNS DLBCL patients, with 77.8% complete response.
  • At 77.6 months median follow-up, 5-year overall survival and progression-free survival rates were both 77.8% for participants.
  • The pilot study involved nine patients receiving ibrutinib, rituximab, and methotrexate, indicating promising treatment viability.
  • Despite the small cohort, no treatment-related deaths occurred, and major adverse events were infrequent in the patient group.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/68e040eda99c246f578b326dhttps://doi.org/10.3389/fonc.2025.1669385
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)2025 · 1 citations
  2. 2Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)2025 · 1 citations
  3. 3Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025
  4. 4Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach2025 · 1 citations
  5. 5Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma2025